MGTX实时信号 | 通过Getagraph.com最大化利润

出售 114194 min ago

@ $6.39

发出时间: 14 Feb 2024 @ 22:30

回报率: -21.75%

上一信号: Feb 13 - 22:30

上一信号: 购买

回报率: -2.44 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	76 678.00
平均成交量	149 232
市值	317.99M
EPS	$0 ( 2024-03-12 )
下一个收益日期	( $-0.500 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.36
ATR14	$0.0100 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Forbes Alexandria	Sell	1 000	Ordinary Shares
2024-03-12	Forbes Alexandria	Sell	2 000	Ordinary Shares
2024-02-29	Giroux Richard	Sell	13 500	Ordinary Shares
2024-01-07	Zeldin Robert K	Sell	13 773	Ordinary Shares
2024-01-14	Giroux Richard	Buy	25 000	Ordinary Shares

INSIDER POWER
-6.05
Last 100 transactions
Buy: 8 402 826 \| Sell: 8 030 781

音量相关性

長: -0.09 (neutral)

短: -0.05 (neutral)

Signal:(51.236) Neutral

MeiraGTx Holdings PLC 相关性

10 最正相关
ZG	0.844
FCAL	0.831
Z	0.824
HYLS	0.82
OPBK	0.817
VCIT	0.805
FMB	0.803

10 最负相关
SOVO	-0.843

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

MeiraGTx Holdings PLC 相关性 - 货币/商品

0.17
( neutral )

0.20
( neutral )

0.00
( neutral )

0.26
( neutral )

0.30
( neutral )

-0.59
( weak negative )

MeiraGTx Holdings PLC 财务报表

Annual	2023
营收:	$14.02M
毛利润:	$287 000 (2.05 %)
EPS:	$-1.490

FY	2023
营收:	$14.02M
毛利润:	$287 000 (2.05 %)
EPS:	$-1.490

FY	2022
营收:	$15.92M
毛利润:	$7.20M (45.21 %)
EPS:	$-3.16

FY	2021
营收:	$37.70M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.800

Financial Reports:

No articles found.

MeiraGTx Holdings PLC

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.